Literature DB >> 22570680

Secondary causes of nonalcoholic fatty liver disease.

Jacob M Kneeman1, Joseph Misdraji, Kathleen E Corey.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is becoming the most common cause of chronic liver disease in the developing world, found in 17-30% of the population in Western countries and 2-4% worldwide. Defined as the accumulation of fatty acid content greater than 5% of liver weight, NAFLD is a spectrum of disease ranging from simple steatosis to nonalcoholic steatohepatitis. The pathophysiology of NAFLD involves increased de novo synthesis of fatty acids in hepatocytes, the retention of lipids due to impaired hepatocyte apolipoprotein secretion or beta-oxidation. The well-known primary causes of NAFLD are obesity, type II diabetes, dyslipidemia, and insulin resistance. However, other less common conditions can cause a similar clinical and histologic picture, and should be considered in patients who present with NAFLD but do not have traditional risk factors. In this review, we discuss uncommon but important causes of NAFLD, including inborn errors of metabolism, iatrogenic causes, viral hepatitis, and nutritional disorders to provide practicing clinicians with an understanding of the less well recognized causes of NAFLD.

Entities:  

Keywords:  fatty liver; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; secondary causes

Year:  2012        PMID: 22570680      PMCID: PMC3342568          DOI: 10.1177/1756283X11430859

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  39 in total

1.  Hepatocyte transplantation as a treatment for glycogen storage disease type 1a.

Authors:  Maurizio Muraca; Giorgio Gerunda; Daniele Neri; Maria-Teresa Vilei; Anna Granato; Paolo Feltracco; Muzio Meroni; Gianpiero Giron; Alberto B Burlina
Journal:  Lancet       Date:  2002-01-26       Impact factor: 79.321

2.  A position statement on NAFLD/NASH based on the EASL 2009 special conference.

Authors:  Vlad Ratziu; Stefano Bellentani; Helena Cortez-Pinto; Chris Day; Giulio Marchesini
Journal:  J Hepatol       Date:  2010-05-07       Impact factor: 25.083

Review 3.  Drug-induced liver disease.

Authors:  J H Lewis; H J Zimmerman
Journal:  Med Clin North Am       Date:  1989-07       Impact factor: 5.456

4.  Recurrent familial hypobetalipoproteinemia-induced nonalcoholic fatty liver disease after living donor liver transplantation.

Authors:  Noboru Harada; Yuji Soejima; Akinobu Taketomi; Tomoharu Yoshizumi; Hideaki Uchiyama; Toru Ikegami; Toshiharu Saibara; Takashi Nishizaki; Yoshihiko Maehara
Journal:  Liver Transpl       Date:  2009-07       Impact factor: 5.799

5.  Oxidative injury and hepatocyte apoptosis in total parenteral nutrition-associated liver dysfunction.

Authors:  Wei Cai; Jiang Wu; Li Hong; Yuanfei Xu; Qingya Tang; Chengren Shi
Journal:  J Pediatr Surg       Date:  2006-10       Impact factor: 2.545

6.  Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function.

Authors:  Sebastian Zeissig; Stephanie K Dougan; Duarte C Barral; Yvonne Junker; Zhangguo Chen; Arthur Kaser; Madelyn Ho; Hannah Mandel; Adam McIntyre; Susan M Kennedy; Gavin F Painter; Natacha Veerapen; Gurdyal S Besra; Vincenzo Cerundolo; Simon Yue; Sarah Beladi; Samuel M Behar; Xiuxu Chen; Jenny E Gumperz; Karine Breckpot; Anna Raper; Amanda Baer; Mark A Exley; Robert A Hegele; Marina Cuchel; Daniel J Rader; Nicholas O Davidson; Richard S Blumberg
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

7.  Diagnosis of Wilson's disease presenting as fulminant hepatic failure.

Authors:  A J McCullough; C R Fleming; J L Thistle; W P Baldus; J Ludwig; J T McCall; E R Dickson
Journal:  Gastroenterology       Date:  1983-01       Impact factor: 22.682

8.  Conditional ablation of mediator subunit MED1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis.

Authors:  Yuzhi Jia; Navin Viswakarma; Tao Fu; Songtao Yu; M Sambasiva Rao; Jayme Borensztajn; Janardan K Reddy
Journal:  Gene Expr       Date:  2009

9.  Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.

Authors:  Fabio Farinati; Romilda Cardin; Renata D'inca; Remo Naccarato; Giacomo Carlo Sturniolo
Journal:  J Lab Clin Med       Date:  2003-06

10.  Glycogen storage disease type III diagnosis and management guidelines.

Authors:  Priya S Kishnani; Stephanie L Austin; Pamela Arn; Deeksha S Bali; Anne Boney; Laura E Case; Wendy K Chung; Dev M Desai; Areeg El-Gharbawy; Ronald Haller; G Peter A Smit; Alastair D Smith; Lisa D Hobson-Webb; Stephanie Burns Wechsler; David A Weinstein; Michael S Watson
Journal:  Genet Med       Date:  2010-07       Impact factor: 8.822

View more
  70 in total

1.  Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice.

Authors:  Ling Yang; Yoon Seok Roh; Jingyi Song; Bi Zhang; Cheng Liu; Rohit Loomba; Ekihiro Seki
Journal:  Hepatology       Date:  2013-12-18       Impact factor: 17.425

2.  The glucocorticoid receptor agonistic modulators CpdX and CpdX-D3 do not generate the debilitating effects of synthetic glucocorticoids.

Authors:  Guoqiang Hua; Naimah Zein; Laetitia Paulen; Pierre Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-20       Impact factor: 11.205

3.  Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export.

Authors:  Fawzi Alogaili; Sivaprakasam Chinnarasu; Anja Jaeschke; Evangelia G Kranias; David Y Hui
Journal:  J Biol Chem       Date:  2020-02-20       Impact factor: 5.157

Review 4.  Signal transductions and nonalcoholic fatty liver: a mini-review.

Authors:  Lu Zeng; Wai J Tang; Jin J Yin; Bei J Zhou
Journal:  Int J Clin Exp Med       Date:  2014-07-15

5.  Gaps in recognition and evaluation of incidentally identified hepatic steatosis.

Authors:  Andrew P Wright; Amit P Desai; Surabhi Bajpai; Lindsay Y King; Dushyant V Sahani; Kathleen E Corey
Journal:  Dig Dis Sci       Date:  2014-09-05       Impact factor: 3.199

Review 6.  Role of xenobiotics in the induction and progression of fatty liver disease.

Authors:  James E Klaunig; Xilin Li; Zemin Wang
Journal:  Toxicol Res (Camb)       Date:  2018-05-18       Impact factor: 3.524

Review 7.  Inborn errors of metabolism in the differential diagnosis of fatty liver disease.

Authors:  Yılmaz Yıldız; Hatice Serap Sivri
Journal:  Turk J Gastroenterol       Date:  2020-01       Impact factor: 1.852

Review 8.  Refeeding syndrome : physiological background and practical management.

Authors:  Aminda De Silva; Jeremy M D Nightingale
Journal:  Frontline Gastroenterol       Date:  2019-12-30

9.  Low-density lipoprotein receptor-related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression.

Authors:  Allyson N Hamlin; Sivaprakasam Chinnarasu; Yinyuan Ding; Xunde Xian; Joachim Herz; Anja Jaeschke; David Y Hui
Journal:  J Biol Chem       Date:  2018-05-11       Impact factor: 5.157

10.  Female Mice are Resistant to Fabp1 Gene Ablation-Induced Alterations in Brain Endocannabinoid Levels.

Authors:  Gregory G Martin; Sarah Chung; Danilo Landrock; Kerstin K Landrock; Lawrence J Dangott; Xiaoxue Peng; Martin Kaczocha; Eric J Murphy; Ann B Kier; Friedhelm Schroeder
Journal:  Lipids       Date:  2016-07-23       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.